BioSpace News Archive

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (T-DM1, Kadcyla®), for patients with locally advanced or metastatic HER2-positive (HER2+) breast cancer

Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced that results from its Phase 3 LIBERTY 1 & 2 studies of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids will be presented in the late-breaking oral session at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress,

BOCAhealth with its ‘body fluids manager’ receives the Pharma Trend 2019 “Most Innovative Product” award in the startups category.

Jennifer Wilson Recognized as a Finalist for Female Executive of the Year

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November

Mr. Klein currently serves as the Executive Vice President and Chief Financial Officer of Constellation Brands, Inc.

Phase 1 clinical trials for their drug candidate, EC5026, for the treatment of pain.

Invited oral presentation at World ADC on Thursday, Oct. 10 at 11:30 AM PT and poster presentation at AACR-NCI-EORTC on Sunday, Oct. 27 at 12:30 PM ET

Pacific Biosciences of California, Inc. announced that more than 50 presentations will include data from the company’s Single Molecule, Real-Time sequencing platforms at next week’s American Society for Human Genetics 2019 annual meeting in Houston.

MediPharm Labs Corp is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. has closed a credit agreement with a top 5 Canadian Schedule 1 bank for an aggregate $38.7 million.